Rhythm Pharmaceuticals, Inc. Forecast, price target & analysts
Rhythm Pharmaceuticals, Inc. Target price 2026 - Analyst rating & recommendation
Rhythm Pharmaceuticals, Inc. Classifications & Recommendation
Rhythm Pharmaceuticals, Inc. Price Target
| Target Price | $140.76 |
| Price | $89.82 |
| Potential |
56.71%
register free of charge
|
| Number of Estimates | 19 |
|
19 Analysts have issued a price target Rhythm Pharmaceuticals, Inc. 2027 .
The average Rhythm Pharmaceuticals, Inc. target price is $140.76.
This is
56.71%
register free of charge
$168.00
87.04%
register free of charge
$106.05
18.07%
register free of charge
|
|
| A rating was issued by 23 analysts: 20 Analysts recommend Rhythm Pharmaceuticals, Inc. to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Rhythm Pharmaceuticals, Inc. stock has an average upside potential 2027 of
56.71%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 189.76 | 319.98 |
| 45.82% | 68.62% | |
| EBITDA Margin | -100.48% | -60.70% |
| 50.46% | 39.59% | |
| Net Margin | -106.41% | -65.82% |
| 47.66% | 38.14% |
19 Analysts have issued a sales forecast Rhythm Pharmaceuticals, Inc. 2026 . The average Rhythm Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Rhythm Pharmaceuticals, Inc. EBITDA forecast 2026. The average Rhythm Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
19 Rhythm Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2026. The average Rhythm Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.11 | -3.06 |
| 28.34% | 1.61% | |
| P/E | negative | |
| EV/Sales | 18.62 |
19 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast for earnings per share. The average Rhythm Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Rhythm Pharmaceuticals, Inc....
Current Rhythm Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RBC Capital |
Locked
➜
Locked
|
Locked | Oct 08 2026 |
| Deutsche Bank |
Locked
➜
Locked
|
Locked | Aug 28 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 05 2026 |
| Citizens |
Locked
➜
Locked
|
Locked | Aug 05 2026 |
| Citigroup |
Locked
➜
Locked
|
Locked | Aug 05 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Jul 27 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
RBC Capital:
Locked
➜
Locked
|
Oct 08 2026 |
|
Locked
Deutsche Bank:
Locked
➜
Locked
|
Aug 28 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 05 2026 |
|
Locked
Citizens:
Locked
➜
Locked
|
Aug 05 2026 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Aug 05 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Jul 27 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
